Company dosed first patient in the Phase III evaluation of VEGF Trap-Eye in wet AMD.

Regeneron Pharmaceuticals received a $20-million milestone fee from Bayer HealthCare. The payment was triggered by Regeneron dosing the first patient in its Phase III study of the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD).

In October, 2006, Bayer coughed up $75 million to partner with Regeneron on the global development of the VEGF Trap-Eye. The company thus also gained ex-U.S. commercialization rights to the drug. Regeneron stands to earn an additional $20 million related to the Phase III trial and $205 million in total milestone payments.

The VEGF Trap-Eye is a fully human, soluble VEGF receptor fusion protein that reportedly binds all forms of VEGF-A along with the related placental growth factor (PlGF). The VEGF Trap-Eye is a specific and highly potent blocker of these growth factors, according to the companies.

This late-stage trial will be a noninferiority comparison of the VEGF Trap-Eye and Genentech’s Lucentis. The randomized, double-masked evaluation is expected to enroll approximately 1,200 patients.

“Results of early-phase studies have shown that VEGF Trap-Eye has the potential to be an important addition to the treatment alternatives available for patients with wet AMD,” reports Leonard S. Schleifer, M.D., Ph.D., president and CEO of Regeneron.

Previous articleSurModics Acquires BioFX Laboratories for $11.3M
Next articleIcagen Inks Multimillion-Dollar Ion-Channel Pact with Pfizer for Pain and Related Indications